Journal
CANCER PREVENTION RESEARCH
Volume 2, Issue 12, Pages 1059-1064Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-09-0221
Keywords
-
Categories
Funding
- NIH [N01CN43308, R01CA113793, R01AT003203, P50CA089019]
- NATIONAL CANCER INSTITUTE [R01CA113793, P50CA089019] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT003203] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In the present study, we examined the effect of bexarotene (Targretin) and budesonide in the chemoprevention of small cell lung carcinoma using a lung-specific knockout model of Rb1 and p53. Upon treatment with bexarotene, tumor incidence, number, and load were significantly reduced (P < 0.05). Budesonide treatment trended to inhibition, but the effect was not statistically significant (P > 0.05). Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors. The Rb1/p53 gene-targeted mouse seems to be a valuable model for chemopreventive studies on human small cell lung cancer. Our results indicate that the retinoid X receptor agonist bexarotene may be a potent chemopreventive agent in this cancer type.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available